Results
|
|
761.
|
|
|
|
762.
|
|
|
|
763.
|
|
|
|
764.
|
|
|
|
765.
|
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. [electronic resource] by
- Blackwood, Elizabeth
- Epler, Jennifer
- Yen, Ivana
- Flagella, Michael
- O'Brien, Tom
- Evangelista, Marie
- Schmidt, Stephen
- Xiao, Yang
- Choi, Jonathan
- Kowanetz, Kaska
- Ramiscal, Judi
- Wong, Kenton
- Jakubiak, Diana
- Yee, Sharon
- Cain, Gary
- Gazzard, Lewis
- Williams, Karen
- Halladay, Jason
- Jackson, Peter K
- Malek, Shiva
Producer: 20140519
In:
Molecular cancer therapeutics vol. 12
Availability: No items available.
|
|
|
766.
|
|
|
|
767.
|
Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. [electronic resource] by
- Prince, Eric W
- Balakrishnan, Ilango
- Shah, Monil
- Mulcahy Levy, Jean M
- Griesinger, Andrea M
- Alimova, Irina
- Harris, Peter S
- Birks, Diane K
- Donson, Andrew M
- Davidson, Nathan
- Remke, Marc
- Taylor, Michael D
- Handler, Michael H
- Foreman, Nicholas K
- Venkataraman, Sujatha
- Vibhakar, Rajeev
Producer: 20180130
In:
Oncotarget vol. 7
Availability: No items available.
|
|
|
768.
|
|
|
|
769.
|
|
|
|
770.
|
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. [electronic resource] by
- Oo, Zay Yar
- Proctor, Martina
- Stevenson, Alexander J
- Nazareth, Deborah
- Fernando, Madushan
- Daignault, Sheena M
- Lanagan, Catherine
- Walpole, Sebastian
- Bonazzi, Vanessa
- Škalamera, Dubravka
- Snell, Cameron
- Haass, Nikolas K
- Larsen, Jill E
- Gabrielli, Brian
Producer: 20200511
In:
Molecular oncology vol. 13
Availability: No items available.
|
|
|
771.
|
|
|
|
772.
|
|
|
|
773.
|
|
|
|
774.
|
|
|
|
775.
|
|
|
|
776.
|
|
|
|
777.
|
|
|
|
778.
|
|
|
|
779.
|
|
|
|
780.
|
|